TY  - JOUR
A1  - Neukam, Karin
A1  - Munteanu, Daniela I.
A1  - Rivero-Juárez, Antonio
A1  - Lutz, Thomas
A1  - Fehr, Jan
A1  - Mandorfer, Mattias
A1  - Bhagani, Sanjay
A1  - López-Cortés, Luis F.
A1  - Haberl, Annette
A1  - Stöckle, Marcel
A1  - Márquez, Manuel
A1  - Scholten, Stefan
A1  - Santos-Gil, Ignacio de los
A1  - Mauß, Stefan
A1  - Rivero, Antonio
A1  - Collado, Antonio
A1  - Delgado, Marcial
A1  - Rockstroh, Jürgen
A1  - Pineda, Juan A.
T1  - Boceprevir or telaprevir based triple therapy against chronic hepatitis C in HIV coinfection : real-life safety and efficacy
T2  - PLoS One
N2  - Background and aims: Clinical trials of therapy against chronic hepatitis C virus (HCV) infection including boceprevir (BOC) or telaprevir (TVR) plus pegylated interferon and ribavirin (PR) have reported considerably higher response rates than those achieved with PR alone. This study sought to evaluate the efficacy and safety of triple therapy including BOC or TVR in combination with PR in HIV/HCV-coinfected patients under real-life conditions.
Methods: In a multicentre study conducted in 24 sites throughout five European countries, all HIV/HCV-coinfected patients who initiated a combination of BOC or TVR plus PR and who had at least 60 weeks of follow-up, were analyzed. Sustained virologic response 12 weeks after the scheduled end of therapy date (SVR12) and the rate of discontinuations due to adverse events (AE) were evaluated.
Results: Of the 159 subjects included, 127 (79.9%) were male, 45 (34.4%) were treatment-naïve for PR and 60 (45.4%) showed cirrhosis. SVR12 was observed in 31/46 (67.4%) patients treated with BOC and 69/113 (61.1%) patients treated with TVR. Overall discontinuations due to AE rates were 8.7% for BOC and 8% for TVR. Grade 3 or 4 hematological abnormalities were frequently observed; anemia 7%, thrombocytopenia 17.2% and neutropenia 16.4%.
Conclusion: The efficacy and safety of triple therapy including BOC or TVR plus PR under real-life conditions of use in the HIV/HCV-coinfected population was similar to what is observed in clinical trials. Hematological side effects are frequent but manageable.
Y1  - 2015
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/37985
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-379853
SN  - 1932-6203
N1  - Copyright: © 2015 Neukam et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
VL  - 10
IS  - (4): e0125080
SP  - 1
EP  - 13
PB  - PLoS
CY  - Lawrence, Kan.
ER  -